Beatriz Llamusí

875 total citations
33 papers, 691 citations indexed

About

Beatriz Llamusí is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Beatriz Llamusí has authored 33 papers receiving a total of 691 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 29 papers in Cellular and Molecular Neuroscience and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Beatriz Llamusí's work include Genetic Neurodegenerative Diseases (25 papers), Muscle Physiology and Disorders (16 papers) and RNA Research and Splicing (10 papers). Beatriz Llamusí is often cited by papers focused on Genetic Neurodegenerative Diseases (25 papers), Muscle Physiology and Disorders (16 papers) and RNA Research and Splicing (10 papers). Beatriz Llamusí collaborates with scholars based in Spain, United Kingdom and France. Beatriz Llamusí's co-authors include Rubén Artero, Estefanía Cerro-Herreros, Juan M. Fernández‐Costa, Amparo García-López, Manuel Pérez‐Alonso, Ariadna Bargiela, María Sabater-Arcis, Enríque Pérez‐Payá, Mar Orzáez and Almudena Ramón‐Cueto and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and PLoS ONE.

In The Last Decade

Beatriz Llamusí

31 papers receiving 684 citations

Peers

Countries citing papers authored by Beatriz Llamusí

Since Specialization

Citations

This map shows the geographic impact of Beatriz Llamusí's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Beatriz Llamusí with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Beatriz Llamusí more than expected).

Fields of papers citing papers by Beatriz Llamusí

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Beatriz Llamusí. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Beatriz Llamusí. The network helps show where Beatriz Llamusí may publish in the future.

Co-authorship network of co-authors of Beatriz Llamusí

This figure shows the co-authorship network connecting the top 25 collaborators of Beatriz Llamusí. A scholar is included among the top collaborators of Beatriz Llamusí based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Beatriz Llamusí. Beatriz Llamusí is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Use of HSALR female mice as a model for the study of myotonic dystrophy type I 2025 ·Lab Animal ·(unknown), (unknown), (unknown), Raquel Pérez-Gómez, (unknown), (unknown), (unknown), Beatriz Llamusí, Estefanía Cerro-Herreros, Rubén Artero	0
2	AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action 2024 ·Science Advances ·Estefanía Cerro-Herreros, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Juan J. Vílchez, Adolfo López de Munaín, Mònica Suelves, Gisela Nogales‐Gadea, Beatriz Llamusí, Rubén Artero	1
3	BlockmiR AONs as Site-Specific Therapeutic MBNL Modulation in Myotonic Dystrophy 2D and 3D Muscle Cells and HSALR Mice 2023 ·Pharmaceutics ·(unknown), Estefanía Cerro-Herreros, (unknown), (unknown), Nerea Moreno, Juan M. Fernández‐Costa, (unknown), Javier Ramón‐Azcón, Manuel Pérez‐Alonso, Thorleif Møller, Beatriz Llamusí, Rubén Artero	5
4	Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression 2023 ·Molecular Therapy — Nucleic Acids ·(unknown), Estefanía Cerro-Herreros, Nerea Moreno, (unknown), (unknown), (unknown), (unknown), Andrey Arzumanov, (unknown), Yahya E. Jad, (unknown), Matthew J. A. Wood, Miguel A. Varela, Beatriz Llamusí, Rubén Artero	10
5	Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model 2022 ·Molecular Therapy — Nucleic Acids ·(unknown), Estefanía Cerro-Herreros, (unknown), Miguel A. Varela, (unknown), Yahya E. Jad, (unknown), Thorleif Møller, Manuel Pérez‐Alonso, Matthew J. A. Wood, Beatriz Llamusí, Rubén Artero	17
6	Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy 2021 ·Molecular Therapy — Nucleic Acids ·Estefanía Cerro-Herreros, (unknown), Nerea Moreno, (unknown), Juan M. Fernández‐Costa, (unknown), (unknown), (unknown), (unknown), Juan J. Vílchez, Adolfo López de Munaín, Miguel A. Varela, Matthew J. A. Wood, Manuel Pérez‐Alonso, Beatriz Llamusí, Rubén Artero	17
7	Defined d-hexapeptides bind CUG repeats and rescue phenotypes of myotonic dystrophy myotubes in a Drosophila model of the disease 2021 ·Scientific Reports ·(unknown), Ariadna Bargiela, Beatriz Llamusí, (unknown), Roger Estrada‐Tejedor, Enrique García‐España, Rubén Artero, Manuel Pérez‐Alonso	0
8	Rabphilin silencing causes dilated cardiomyopathy in a Drosophila model of nephrocyte damage 2021 ·Scientific Reports ·(unknown), (unknown), Rubén Artero, Beatriz Llamusí, Juan A. Navarro, Josep Redón	5
9	Rabphilin involvement in filtration and molecular uptake in Drosophila nephrocytes suggests a similar role in human podocytes 2020 ·Disease Models & Mechanisms ·(unknown), Beatriz Llamusí, Juan M. Fernández‐Costa, (unknown), Rubén Artero, Josep Redón	8
10	Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy 2020 ·Molecular Therapy — Nucleic Acids ·Estefanía Cerro-Herreros, (unknown), (unknown), (unknown), Manuel Pérez‐Alonso, Beatriz Llamusí, Rubén Artero	35
11	Daunorubicin reduces MBNL1 titration by expanded CUG repeat RNA and rescues cardiac dysfunctions in a Drosophila model of myotonic dystrophy 2018 ·Disease Models & Mechanisms ·(unknown), Chantal Sellier, (unknown), Pascal Villa, Nicolas Charlet‐Berguerand, Rubén Artero, Beatriz Llamusí	13
12	miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models 2018 ·Nature Communications ·Estefanía Cerro-Herreros, María Sabater-Arcis, Juan M. Fernández‐Costa, Nerea Moreno, Manuel Pérez‐Alonso, Beatriz Llamusí, Rubén Artero	66
13	rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences 2018 ·Nature Communications ·Chantal Sellier, Estefanía Cerro-Herreros, Markus Blatter, Fernande Freyermuth, Angéline Gaucherot, Frank Ruffenach, Partha S. Sarkar, Jack Puymirat, Bjarne Udd, John Day, G. Meola, Guillaume Bassez, Harutoshi Fujimura, Masanori Takahashi, Benedikt Schoser, Denis Furling, Rubén Artero, Frédéric H.‐T. Allain, Beatriz Llamusí, Nicolas Charlet‐Berguerand	57
14	Optical Cross-Sectional Muscle Area Determination of <em>Drosophila Melanogaster</em> Adult Indirect Flight Muscles 2018 ·Journal of Visualized Experiments ·(unknown), Rubén Artero, Beatriz Llamusí	5
15	Modeling of Myotonic Dystrophy Cardiac Phenotypes in Drosophila 2018 ·Frontiers in Neurology ·(unknown), Beatriz Llamusí, Rubén Artero	10
16	Expanded CCUG repeat RNA expression in Drosophila heart and muscle trigger Myotonic Dystrophy type 1-like phenotypes and activate autophagocytosis genes 2017 ·Scientific Reports ·Estefanía Cerro-Herreros, (unknown), Manuel Pérez‐Alonso, Rubén Artero, Beatriz Llamusí	17
17	The Drosophila junctophilin gene is functionally equivalent to its four mammalian counterparts and is a modifier of a Huntingtin poly-Q expansion and the Notch pathway 2017 ·Disease Models & Mechanisms ·Eduardo Calpena, Víctor López Del Amo, (unknown), Beatriz Llamusí, Rubén Artero, Carmen Espinós, Máximo Ibo Galindo	14
18	In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models 2017 ·PLoS ONE ·(unknown), (unknown), Beatriz Llamusí, Estefanía Delgado‐Pinar, José I. Borrell, Jordi Teixidó, Enrique García‐España, Manuel Pérez‐Alonso, Roger Estrada‐Tejedor, Rubén Artero	11
19	Alternative splicing regulation by Muscleblind proteins: from development to disease 2011 ·Biological reviews/Biological reviews of the Cambridge Philosophical Society ·Juan M. Fernández‐Costa, Beatriz Llamusí, Amparo García-López, Rubén Artero	41
20	A GFP-tagged Muscleblind C protein isoform reporter construct 2010 ·Fly ·(unknown), Lidón Monferrer, Juan M. Fernández‐Costa, Ariadna Bargiela, Rubén Artero, Beatriz Llamusí	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact